
Shares of telehealth company Hims & Hers Health HIMS.N fall 4% to $16.01 in afternoon trading, on track for their tenth straight day of losses
Last week, HIMS said it would launch a $49 compounded version of Novo Nordisk's Wegovy pill for weight loss, which was then withdrawn after scrutiny from the U.S. health regulator
Co's shares fell further after Danish drugmaker Novo sued HIMS over patent infringement of semaglutide, the active ingredient in Wegovy
Novo has sued several compounders for allegedly selling unsafe, falsely advertised Wegovy "knockoffs" that violate its trademark rights, but the Hims lawsuit is its first U.S. patent case against a compounder
Up to last close, HIMS down 50% YTD